These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24687506)

  • 1. Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies.
    Okusanya OO; Bhavnani SM; Hammel JP; Forrest A; Bulik CC; Ambrose PG; Gupta R
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5005-15. PubMed ID: 24687506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection.
    Okusanya OO; Bhavnani SM; Hammel J; Minic P; Dupont LJ; Forrest A; Mulder GJ; Mackinson C; Ambrose PG; Gupta R
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3847-54. PubMed ID: 19451281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Bilton D; Pressler T; Fajac I; Clancy JP; Sands D; Minic P; Cipolli M; Galeva I; Solé A; Quittner AL; Liu K; McGinnis JP; Eagle G; Gupta R; Konstan MW;
    J Cyst Fibros; 2020 Mar; 19(2):284-291. PubMed ID: 31451351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection.
    Bilton D; Fajac I; Pressler T; Clancy JP; Sands D; Minic P; Cipolli M; Galeva I; Solé A; Quittner AL; Jumadilova Z; Ciesielska M; Konstan MW;
    J Cyst Fibros; 2021 Nov; 20(6):1010-1017. PubMed ID: 34144923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection.
    Clancy JP; Dupont L; Konstan MW; Billings J; Fustik S; Goss CH; Lymp J; Minic P; Quittner AL; Rubenstein RC; Young KR; Saiman L; Burns JL; Govan JR; Ramsey B; Gupta R;
    Thorax; 2013 Sep; 68(9):818-25. PubMed ID: 23749840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amikacin target achievement in adult cystic fibrosis patients utilizing Monte Carlo simulation.
    Nolt VD; Pijut KD; Autry EB; Williams WC; Burgess DS; Burgess DR; Arora V; Kuhn RJ
    Pediatr Pulmonol; 2019 Jan; 54(1):33-39. PubMed ID: 30507069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.
    Sutharsan S; Naehrig S; Mellies U; Sieder C; Ziegler J
    BMC Pulm Med; 2020 Jun; 20(1):167. PubMed ID: 32532226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.
    Ehsan Z; Clancy JP
    Future Microbiol; 2015; 10(12):1901-12. PubMed ID: 26573178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
    Chan E; Zhou S; Srikumar S; Duan W
    Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
    McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
    Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.
    Milla CE; Chmiel JF; Accurso FJ; VanDevanter DR; Konstan MW; Yarranton G; Geller DE;
    Pediatr Pulmonol; 2014 Jul; 49(7):650-8. PubMed ID: 24019259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of tobramycin in patients with cystic fibrosis.
    Mouton JW; Jacobs N; Tiddens H; Horrevorts AM
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):123-7. PubMed ID: 15964500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of three dosage regimens of amikacin using pharmacokinetic models in patients with cystic fibrosis].
    Halacová M; Průsa R; Kotaska K; Vávrová V
    Cas Lek Cesk; 2004; 143(3):187-90. PubMed ID: 15134039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections.
    Meers P; Neville M; Malinin V; Scotto AW; Sardaryan G; Kurumunda R; Mackinson C; James G; Fisher S; Perkins WR
    J Antimicrob Chemother; 2008 Apr; 61(4):859-68. PubMed ID: 18305202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou QT; Cheah SE; Zhao J; Chen K; Wang J; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
    Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
    Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Ehsan Z; Wetzel JD; Clancy JP
    Expert Opin Investig Drugs; 2014 May; 23(5):743-9. PubMed ID: 24597573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.